Advances in the engineering of living probiotics for cancer immunotherapy
Theranostics · 01.01.2026 · 16 (3) · 1164-1226
DOI: 10.7150/thno.125301 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Theranostics, erschienen am 01.01.2026. Verfasst von Sibtain Muhammad und 10 weiteren Autor:innen. Beteiligte Einrichtung: School of Science, Harbin Institute of Technology, Shenzhen 518055, China. Hauptthemen laut MEDLINE: Probiotics, Neoplasms, Immunotherapy. Die Arbeit wurde bisher 31-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
The role of bacteria in tumor development has been increasingly recognized through advances in sequencing technologies, revealing their influence on the tumor microenvironment and immune system. Live bacterial therapy, known for its unique ability to target tumors, colonize cancerous tissues, and activate immune responses, is emerging as a novel approach to cancer treatment. To enhance the therapeutic efficacy and safety of this strategy, various engineering techniques have been developed to modify bacteria, enabling the creation of advanced bacteria-based drug delivery systems. Living probiotics can selectively colonize the tumor microenvironment, where they interact with immune cells to enhance antitumor responses. This review provides an overview of the complex relationship between bacteria and tumors and discusses engineering methods for bacterial modification, including physicochemical approaches and synthetic biology. It further highlights the applications of these strategies in enhancing cancer therapies. Finally, it examines the future opportunities for engineered bacteria in cancer therapy, focusing on the potential of combination therapies, personalized medicine, and the role of the microbiome in enhancing therapeutic outcomes. With ongoing advancements, engineered bacteria hold great promise for improving the efficacy and safety of cancer treatments, offering a new frontier in oncology.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- School of Science, Harbin Institute of Technology, Shenzhen 518055, China.
- Department of Radiology, Shenzhen Nanshan People's Hospital (NSPH), 89 Taoyuan Road, Nanshan District, Shenzhen 518052, China.
- Department of Radiology, Shenzhen People's Hospital (The Second Clinical Medical College, Jinan University; The First Affiliated Hospital, Southern University of Science and Technology), Shenzhen 518020, Guangdong, Chin…
- Shenzhen Key Laboratory of Advanced Functional Carbon Materials Research and Comprehensive Application, Harbin Institute of Technology, Shenzhen 518055, China.
- Department of Gynecology, Shenzhen Traditional Chinese Medicine Hospital, The Fourth Clinical Medical College of Guangzhou University of Chinese Medicine, No. 1, Fuhua Road, Futian District, Shenzhen 518033, China.
Zitieren
APA
Muhammad, S., Li, M., Jia, Q., Ijaz, M., Liang, S., Zeng, W., Chen, D., Zhang, Y., Du, X., Song, W., & Guo, B. (2026). Advances in the engineering of living probiotics for cancer immunotherapy. Theranostics, 16(3), 1164-1226. https://doi.org/10.7150/thno.125301
Vancouver
Muhammad S, Li M, Jia Q, Ijaz M, Liang S, Zeng W, et al. Advances in the engineering of living probiotics for cancer immunotherapy. Theranostics. 2026;16(3):1164-1226. doi:10.7150/thno.125301
BibTeX
@article{Muhammad2026,
author = {Muhammad, Sibtain and Li, Menglong and Jia, Qingyun and Ijaz, Muhammad and Liang, Shiqi and Zeng, Wenjun and Chen, Dongxiang and Zhang, Yinghe and Du, Xuelian and Song, Wencong and Guo, Bing},
title = {Advances in the engineering of living probiotics for cancer immunotherapy},
journal = {Theranostics},
year = {2026},
volume = {16},
number = {3},
pages = {1164--1226},
doi = {10.7150/thno.125301}
}
EUVIMED